WUXI BIOLOGICS IRELAND LTD has a total of 53 patent applications. It increased the IP activity by 480.0%. Its first patent ever was published in 2017. It filed its patents most often in EPO (European Patent Office), United States and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are GO THERAPEUTICS INC, BIOND BIOLOGICS LTD and ULTRAHUMAN SIX LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 13 | |
#2 | United States | 11 | |
#3 | Canada | 5 | |
#4 | Republic of Korea | 5 | |
#5 | Singapore | 5 | |
#6 | Australia | 4 | |
#7 | Brazil | 4 | |
#8 | Israel | 4 | |
#9 | WIPO (World Intellectual Property Organization) | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Li Jing | 44 |
#2 | Wang Zhuozhi | 17 |
#3 | Liu Jieying | 16 |
#4 | Xu Jianqing | 12 |
#5 | Mei Qin | 12 |
#6 | Chen Yunying | 9 |
#7 | Zheng Yong | 6 |
#8 | Wu Qiong | 5 |
#9 | Jing Li | 4 |
#10 | Zhuozhi Wang | 2 |
Publication | Filing date | Title |
---|---|---|
EP3802622A1 | A novel anti-cd3/anti-cd20 bispecific antibody | |
WO2019179365A1 | Novel anti-lag-3 antibody polypeptide | |
WO2019165982A1 | Monoclonal antibody against human lag-3, method for preparing same, and use thereof | |
SG11202002261VA | Novel bispecific polypeptide complexes | |
US2020283523A1 | Novel bispecific cd3/cd19 polypeptide complexes | |
SG11202001817PA | Novel anti-cd19 antibodies | |
US2021061912A1 | Novel anti-pd-1 antibodies | |
US2020165354A1 | Novel Anti-PCSK9 Antibodies |